Atorvastatin

Price ceilings, issued by the National Pharmaceutical Pricing Authority (NPPA), cover medicines used to treat various conditions ranging from infections, heart ailments, and inflammation to diabetes and vitamin deficiencies.

Morepen Labs Reports 118 Per Cent Jump in Net Profits for the Q2 of FY 2016-17, Backed by a Good Performance in API and Dr. Morepen Health Basket

Morepen Laboratories Ltd. has reported a 118 per cent rise in its net profit (profit after tax) for the Second quarter (Q2) of FY ...

NeoBiocon partners with Novartis for diabetes drug in UAE

Speaking to CNBC-TV18, Dr Arun Chandavarkar, CEO & Joint MD, Biocon says that the company is also looking to introduce its biosimilars and insulin portfolio in the UAE.

Sun Pharma up 3%, raises Ranbaxy's products prices in US

Brokerage Credit Suisse said Sun Pharma has taken price increases in six of Ranbaxy's branded products in the US in May 2015.

Ranbaxy Q4 net loss at Rs 492 cr, sales fall 29%

Pharma major Ranbaxy reported a fourth quarter consolidated net loss of Rs 492 crore, lower than the Rs 2,983 crore loss it reported a year ago.

Ranbaxy up on restart of Atorvastatin production in the US

Ranbaxy shares rose over 4 percent in morning trade after the drug maker said it has resumed production of the drug substance for its Atorvastatin cholesterol lowering drug in United States.

Parl stalemate: Not very optimistic about Mon, says Tulsian

In an interview to CNBC-TV18, SP Tulsian of Sptulsian.com informed that they have scheduled this all party meet on Monday to discuss on FDI. He feels that this is seen more as a political agenda and nobody is interested in having a healthy discussion.

Ranbaxy recalls Atorvastatin from US market, stock slips 2%

Shares of drug maker Ranbaxy slipped over 2 percent on Friday after the company said it was recalling some batches of its cholesterol lowering drug Atorvastatin (generic version of Pfizer's Lipitor) from the US market, and supplies would be affected until an investigation is completed.

Ind-Swift launches Atorvastatin Tablets in UK

Ind-Swift added another feather in its cap by launching generic formulations of the World‘s best selling drug Atorvastatin in UK in collaboration with Wockhardt UK Ltd. on the first day of its patent expiry.

Ranbaxy Q1 jumps 300%, What are analysts saying?

Pharma major Ranbaxy on Wednesday beat street estimates with a four-fold year-on-year jump in first quarter net profit at Rs 1,247 crore. However, many analysts were unimpressed on the results, which were boosted mainly by forex gains and strong sales of its copy of cholesterol lowering drug Lipitor.

Ranbaxy Q1 net jumps 310%; to set up new plant in Nigeria

Pharma major Ranbaxy on Wednesday beat street estimates with a four-fold year-on-year increase in first quarter net profit at Rs 1,247 crore, helped by strong sales including that of its cholesterol lowering drug Atorvastatin in the US market, and forex gains.

Ranbaxy Q1 net jumps 310% YoY on robust sales, forex gains

Pharma major Ranbaxy Wednesday reported a significantly better-than-expected four-fold year-on-year increase in consolidated net profit at Rs 1,247 crore, helped by strong sales growth, higher other income and forex gains.

Ranbaxy launches cholesterol lowering drug in 4 EU states

Pharma major Ranbaxy has launched its generic version of cholesterol lowering drug Atorvastatin in Italy, Sweden and Netherlands having received approval from local regulatory authorities.

Ranbaxy jumps after final nod from USFDA to launch Lipitor

Ranbaxy’s shares jumped over 10% in morning trade on Thursday after it said it has launched its generic version of Lipitor in the US market having received final approval from US Food and Drugs Administration (FDA).

Ranbaxy shares end down 7% as Mylan sues FDA to block Lipitor launch

Ranbaxy shares plunged 7% to close at Rs 435.95 Monday after US company Mylan Inc sued the US Foods and Drug Administration for an injunction on the launch of Ranbaxy’s cholesterol treatment drug, Atorvastatin, which is a generic version of Pfizer’s Lipitor.